[O-33] Clinical trial and Regenerative medicine2

[O-33-5] Efficacy & Safety of satralizumab in subgroup of Asian-region patients with NMOSD in SAkuraSky study

Manabu Araki¹, Kazuo Fujihara², Ching-piao Tsai³, Masayuki Haramura⁴, Yusuke Terada⁴, Yuichi Kawata⁴, Takashi Yamamura⁵ (1.Department of neurology, Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan, 2.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine and Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, 3.Neurological Institute, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan, 4.Chugai Pharmaceutical Co., Ltd, 5.Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry)